Kaufman, Howard L. http://orcid.org/0000-0003-1131-004X
Schwartz, Lawrence H.
William, William N. Jr
Sznol, Mario
Fahrbach, Kyle
Xu, Yingxin
Masson, Eric
Vergara-Silva, Andrea
Funding for this research was provided by:
AstraZeneca (N/A)
Article History
Received: 3 August 2018
Accepted: 9 August 2018
First Online: 21 August 2018
Compliance with ethical standards
:
: HLK received fees from Compass Therapeutics for a leadership role, received fees from Amgen, Celldex Therapeutics, EMD Serono, Prometheus, Merck, Sanofi, and Turnstone Biologics for consulting/advisory activities, and received funds from EMD Serono, Sanofi, and Turnstone Biologics for travel/accommodations, and Howard L. Kaufman’s institution received research funding from Amgen and Merck as well as funds from Merck for Speakers’ Bureau activities. LHS received fees from Novartis and Merck for being a member of the Data and Safety Monitoring Board, for imaging endpoints. WNW Jr: his institution received research funding from Merck, Eli Lilly, Astellas Pharma, Bristol-Myers Squibb. MS has nothing to declare. KF is an employee of Evidera. YX was an employee of Evidera, now an employee of Regeneron Pharmaceuticals. EM was an employee of and owns shares of stock in AstraZeneca, now an employee of Biogen. AVS was an employee of and owns shares of stock in AstraZeneca, now an employee of Ayala Pharmaceuticals.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.